Micro Labs Chief Dilip Surana Dismantles Trump’s Claim: Science Shows No Autism Risk from Paracetamol

Dilip Surana’s rebuttal to Trump’s autism-paracetamol claim is backed by global scientific consensus and WHO’s latest clarification, reinforcing Dolo-650’s leadership in India’s pharmaceutical landscape.

Dilip Surana Defends Paracetamol Use in Pregnancy, Rebukes Trump’s Autism Claim with Scientific Rigor. In a moment of clarity amid global misinformation, Dilip Surana, Visionary Award-winning entrepreneur and Chairman of Micro Labs, has emerged as a voice of reason. Responding to President Donald Trump’s controversial claim linking paracetamol use during pregnancy to autism, Surana emphasized that “the global scientific consensus does not support such a link,” citing the World Health Organization’s (WHO) recent clarification that evidence remains inconsistent and lacks replicability.

Surana’s remarks come at a critical juncture, as Trump’s statements have elevated unverified claims to the forefront of U.S. health policy. The WHO, in its September 24 statement, reiterated that “no conclusive scientific evidence confirms a link between autism and acetaminophen (paracetamol) use during pregnancy.” It further stressed that childhood vaccines do not cause autism, discrediting earlier flawed studies.

Surana warned against the dangers of misinformation-driven avoidance of treatment:

“Untreated fever during pregnancy can pose risks to both the mother and the foetus, making it essential to manage such symptoms appropriately.”

He urged that claims must be weighed against established research, noting that “the most rigorous studies have not found a link” between paracetamol and autism. His stance aligns with WHO’s guidance that medications during pregnancy should be used cautiously and under medical supervision, especially in the first trimester.

Dolo-650: India’s Paracetamol Powerhouse

Micro Labs’ flagship brand Dolo-650 continues to dominate India’s pharmaceutical market:

• ₹300 crore in moving annual total (MAT) sales as of July 2025, according to IQVIA
• Most prescribed paracetamol in India, accounting for 0.66% of total prescriptions between November 2024 and February 2025

Surana also highlighted the Indian context, noting that expectant mothers in India are known for their vigilance, and that medical professionals are well-equipped to guide safe medication use.

Editorial Takeaway

This is not just a rebuttal—it’s a reaffirmation of evidence-based healthcare. Dilip Surana’s intervention underscores the responsibility of pharmaceutical leadership in countering misinformation and safeguarding public trust. As Dolo-650 continues to lead in prescriptions and sales, Micro Labs positions itself not only as a market leader but as a guardian of scientific integrity.